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Summary 
 The Department of Defence and the Department of Veterans’ Affairs commissioned The University 
of Queensland to use data from 2007/8 studies of deployment to East Timor, Bougainville and the 
Solomon Islands to investigate the issue of anti-malarial drugs and long-term health.  
 
 This report presents the results of a descriptive analysis of self-reported anti-malarial drug use on 
deployment and self-reported physical and mental health.  The analysis focused on the East Timor 
and Bougainville studies.   
 
 Sixty-six military members who deployed to East Timor reported mefloquine use, and 27 members 
who deployed to Bougainville reported mefloquine use. The self-reported health of these 
members was compared with members who did not take mefloquine.  
 
 Twenty per cent of these East Timor veterans, and 11% of these Bougainville veterans who used 
mefloquine reported that they had a significant reaction to this drug. Between 4 and 5% of 
veterans who used doxycycline reported having a significant reaction.   
 
 East Timor and Bougainville veterans who used mefloquine on deployment reported more 
symptoms of psychological distress than those who used other drugs. However, the average 
differences observed were below the threshold of clinical significance and based on a small sample 
size in the mefloquine group. 
 
 Bougainville veterans who used mefloquine on deployment were more likely to report poorer 
general health and more general health symptoms than veterans who did not use mefloquine.  
However, these associations were not observed in the East Timor study.   
 
 Fifty-seven respondents (1.6%) to the East Timor and Bougainville studies mentioned use of anti-
malarial drugs as an area of concern in response to open-ended questions. 
 
 There was no clear association between doxycycline or primaquine use and self-reported physical 
or mental health in the analyses undertaken. 
 
 The results presented in this report should be interpreted with caution due to the small sample 
size of mefloquine users included in the analysis, and the cross-sectional design of the studies.   
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1. Introduction 
1.1 Study overview 
 
In August 2017, the Repatriation Medical Authority (RMA) released the results of an investigation into 
chemically acquired brain injury caused by the anti-malarial drugs mefloquine, tafenoquine and 
primaquine [1]. These drugs have been used by Australian Defence Force (ADF) personnel on 
deployments and there is concern among some veterans about their long-term health effects. The 
RMA investigation concluded that there is insufficient sound-medical-scientific evidence that 
exposure to these drugs can cause chronic brain injury.  However, the RMA noted that the clinical 
trials used to assess the safety of these drugs did not include longer term follow-up of participants.   
 
The present study is the first to investigate associations between different types of anti-malarial drugs 
used by ADF personnel and health status several years after use. The Department of Defence and 
Department of Veterans’ Affairs (DVA) commissioned The University of Queensland (UQ) to use data 
from published health studies of ADF deployments to Bougainville, Solomon Islands and East Timor to 
investigate such associations. These cross-sectional, self-report, survey studies, undertaken in 2007 
and 2008, asked respondents to name what anti-malarial drugs they used on deployment and any 
reactions they had to them, and to complete a number of validated measures of current general and 
mental health.  Respondents could also answer open-ended questions.  
 
This descriptive analysis will present self-reported reactions to anti-malarial drugs and examine 
associations between the use of mefloquine, primaquine and doxycycline and self-reported physical 
and mental health.  Associations with tafenoquine will not be examined in this study as the number 
of study respondents who reported that they took this drug was too low to permit proper 
investigation. 
 
1.2 Research questions 
 
1. Did deployed veterans report a significant reaction to anti-malarial drugs received during their 
deployment? 
2. Did deployed veterans who reported taking mefloquine during their deployment have different 
rates of mental health outcomes compared to veterans who reported taking doxycycline, or other 
anti-malarial drugs? 
3. Did deployed veterans who reported taking mefloquine during their deployment have different 
rates of general health outcomes compared to veterans who reported taking doxycycline, or other 
anti-malarial drugs? 
4. Did deployed veterans who reported taking primaquine on return to Australia have different rates 
of mental health outcomes compared to veterans who reported they did not take primaquine on 
return to Australia? 
5. Did deployed veterans who reported taking primaquine on return to Australia have different rates 
of general health outcomes compared to veterans who reported they did not take primaquine on 
return to Australia? 
6. Did deployed veterans mention previous use of anti-malarial drugs as an area of concern in 
response to open-ended questions, and what was the nature of these responses? 
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1.3 Anti-malarial use on Bougainville, Solomon Islands and East Timor deployments 
 
Deployments to Bougainville commenced in November 1997 and concluded in August 2003. 
Deployments to East Timor commenced in June 1999 and concluded in March 2013, with the bulk of 
personnel deployed over 1999 to 2002. Deployments to the Solomon Islands commenced in 
November 2000 and concluded in August 2013.  
 
Malaria is endemic in each of these locations.  Deployed personnel were therefore required to take 
pre-exposure and post-exposure prophylactic drugs to reduce the chance of infection.  Doxycycline 
was the pre-exposure prophylactic and primaquine the post-exposure prophylactic used by the 
majority of personnel on these deployments.  Personnel who were intolerant to doxycycline were 
prescribed mefloquine (with a small number prescribed Malarone (atovaquone/proguanil) or 
chloroquine). 
 
During the Bougainville and East Timor deployments, mefloquine and a then experimental anti-
malarial called tafenoquine were tested by the Australian Army Malaria Institute to determine their 
efficacy, tolerability and safety. Tafenoquine was trialled for both pre-exposure and post exposure 
prophylaxis (i.e. for both prevention and eradication).  Details about the trials of these drugs is shown 
in Table 1. 
 
Table 1. Details on anti-malarial drug trials with ADF personnel  
 Timeframe Deployment Trial drug n Comparator n Reference 
1 Nov 1998 – Sept 1999 Bougainville Tafenoquine 378 Primaquine 
 
214 [2] 
2  Feb 1999 – Apr 2000 East Timor Tafenoquine 636 Primaquine 
 
289 [3] 
3  Oct 2000 – Apr 2001 East Timor Tafenoquine 492 Mefloquine 162 [4] 
4 Apr 2001 – May 2002  East Timor Mefloquine 1157 Doxycycline 388 [5] 
 
As shown in the Table, mefloquine was only examined in the trials that occurred in East Timor.  
Therefore the only personnel who took mefloquine during the Bougainville or Solomon Islands 
deployments were likely to be intolerant to doxycycline. The number of personnel who took 
mefloquine on each deployment location because they were intolerant to doxycycline is unknown. 
The Department of Defence states that centralised medicines dispensing information has only been 
available in the ADF since 2000 [6]; records show that, outside of the trials, 94 personnel were 
prescribed mefloquine in 2001, 77 in 2002, 69 in 2003, 67 in 2004 and 73 in 2005, with the numbers 
generally falling each year to 20 in 2013 [7]. 
 
1.4 Reported adverse reactions to anti-malarial drugs 
 
Reports from clinical trials, survey studies and case studies have detailed adverse reactions to anti-
malarial drugs.  These reports feed into the product inserts that are produced by the drug’s 
manufacturer to inform consumers about potential side effects and their reported frequency.  
Details on adverse reactions to anti-malarial drugs are available in a summarised form in the 
Australian Medicines Handbook and these are shown in Table 2.  
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Table 2. Adverse reactions associated with Doxycycline, Mefloquine and Primaquine1 
Doxycycline 
Common (>1%) Nausea, vomiting, diarrhoea, epigastric burning, tooth discolouration, enamel 
dysplasia, photosensitivity 
Infrequent (0.1-1%) Rash, stomatitis, bone deformity, fungal overgrowth 
Mefloquine 
Common (>1%) Nausea, vomiting, diarrhoea, abdominal pain, headache, vertigo, dizziness 
(dose-dependent), somnolence, sleep disorders (insomnia, abnormal dreams) 
Infrequent (0.1-1%) Rash, myalgia, dyspnoea, sensory and motor neuropathies, visual 
disturbances, elevated liver enzyme concentrations, chest pain, tachycardia, asymptomatic 
bradycardia, neuropsychiatric disorders2, seizures 
Primaquine 
Common (>1%) Abdominal pain, nausea and vomiting, dizziness, headache, leucocytosis 
Infrequent (0.1-1%) Methaemoglobinaemia 
1 [8-10] 
2 “Disorders such as anxiety, panic attacks, agitation, aggression, acute psychosis, depression, forgetfulness, 
encephalopathy, can occur and may be prolonged” 
 
Information on adverse reactions to anti-malarial drugs in Australia is also available from the 
Therapeutic Goods Administration (TGA).  The TGA maintain a Database of Adverse Event Notifications 
for Medicines that contains reports that are voluntarily provided by members of the public and health 
professionals and mandatory reports of serious adverse events provided by drug manufacturers [11]. 
The TGA uses this database to identify when a safety issue may be present; however, an adverse event 
report does not mean that the medicine is the cause of the event.  Table 3 shows reported adverse 
events associated with mefloquine, doxycycline and primaquine. 
 
Table 3. Top 10 adverse events reported to the TGA for doxycycline, mefloquine and primaquine1 
Doxycycline2 Mefloquine3 Primaquine4 
Reaction term Cases Reaction term Cases Reaction term Cases 
Photosensitivity 150 Depression 55 Methaemoglobinaemia 15 
Rash 136 Dizziness 53 Headache 5 
Pruritus  130 Nausea 52 Diarrhoea 5 
Nausea 114 Anxiety 51 Abdominal pain 4 
Urticaria 90 Headache 29 Nausea 4 
Rash maculo-papular 72 Nightmare 28 Fatigue 4 
Rash erythematous 68 Insomnia 24 Pruritus 4 
Vomiting 67 Agitation 22 Tinnitus 4 
Diarrhoea 60 Abdominal pain 19 Cyanosis 4 
Abdominal pain 58 Diarrhoea 17 Rash 3 
1 [12-14] 
2 First report 11/1972, most recent 04/2018 3 First report 01/1990, most recent 05/2018 4 First report 07/1973, 
most recent 04/2016 
 
Adverse reactions to the anti-malarial drugs trialled with ADF personnel are reported in the published 
papers about the trials.  Table 4, constructed from a table provided in the paper describing trial 4 (East 
Timor, refer to Table 1), shows the adverse events self-reported by soldiers who took mefloquine or 
doxycycline. Adverse event reporting is expected to be higher in studies as adverse events are 
specifically asked for, whereas reports from general population surveillance rely on individuals making 
a voluntary report.  
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Table 4. Most commonly reported adverse events by soldiers who took Mefloquine (n=536) or 
Doxycycline (n=388) in a clinical trial1  
Adverse event Mefloquine n (%) Doxycycline n (%) 
Sleep disturbance 161 (30.4) 83 (21.4) 
Nausea 112 (20.9) 83 (21.4) 
Tiredness 92 (17.5) 95 (24.5) 
Headache  71 (13.2) 69 (17.8) 
1 Constructed from [5] Kitchener, S.J., et al 2005 
 
Adverse events to tafenoquine and mefloquine in trial 3 (East Timor, refer to Table 1) that were 
attributed to use of these drugs (reported adverse events that have been determined by a medical 
professional to most likely have been caused by the drug used) were presented in a Table in the paper 
that described this trial – this Table is shown in Figure 1.  
 
 
Figure 1. Table 5 from [4]. Nasveld, P.E., et al 2010 
 
1.5 Literature on mefloquine and long-term health outcomes 
 
Long-term health is defined here as health outcomes several years after use of mefloquine. Two 
population studies (published in 2015 and 2018) examined the long-term health of people who have 
taken mefloquine.  The 2015 study [15] examined health in people who had had an adverse reaction 
to mefloquine and the 2018 study [16] compared the health of a group of people who had taken 
mefloquine with those who received other anti-malarial drugs.   
 
Ringqvist and colleagues looked at the health of civilians who had reported adverse reactions to 
mefloquine to a Danish National Register [15].  Seventy-three people who had reported an adverse 
reaction between January 1996 and August 2000 were followed up in September-November 2000 
with a questionnaire. The mean time span from onset of adverse reactions to filling out a 
questionnaire was 2.7 years.  Among other measures, the respondents completed subscales from the 
Short-Form-36 (SF-36), a self-report measure of current general and mental health [17]. The study 
found that people who had adverse reactions to mefloquine had worse long-term mental health 
outcomes, as measured by the SF-36, compared to matched controls.  
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The subscales that were statistically significantly lower (p<0.01) were ‘vitality’, ‘role emotional’ and 
‘mental health’.  The vitality subscale asks questions about energy and fatigue (e.g. Did you feel worn 
out?) in the past four weeks on a six-item Likert scale that ranges from ‘none of the time’ to ‘all of the 
time’.  The role emotional subscale asks if emotional problems had an impact (yes or no) on work and 
daily activities in the past four weeks (e.g. accomplished less than you would like).  The mental health 
subscale asks questions about emotional state (e.g. how much of the time have you felt downhearted 
and blue) in the past four weeks on the same Likert scale as for the vitality subscale. 
 
No difference was found between the mefloquine group and the matched controls on the physical 
health subscale of the SF-36.  In discussing their findings, the authors hypothesised that the adverse 
reactions to mefloquine may have signified a stressful life event that could have increased the risk of 
long-term poorer mental health.   
 
Schneiderman and colleagues conducted a survey of US military personnel who deployed to the 
Middle East between 2001 and 2008 to examine associations between anti-malarial drug use and 
health outcomes [16]. Survey data was collected from 2009 to 2011–one to ten years after the 
deployments. From 3,435 respondents who could name the anti-malarial drug they received, 23.3% 
reported using mefloquine (alone or with other anti-malarial drugs).  
 
The respondents completed the Short-Form-12, the Post-Traumatic Stress Disorder Checklist (both 
detailed in section 2.1 of this report) and the Patient Health Questionnaire, an instrument that screens 
for common mental disorders by asking questions about being bothered by problems in the past two 
weeks (e.g. little interest or pleasure in doing things), scored on a 4-item Likert scale.  Having adjusted 
for combat exposure, no significant associations between the use of mefloquine and adverse mental 
and physical health outcomes were found.  
 
1.6 The present study 
 
In this report we will undertake a descriptive analysis of anti-malarial drug use and the self-reported 
physical and mental health of study respondents. Each study asked specific questions about anti-
malarial drug use on deployment and also collected free-text information where respondents could 
highlight health concerns.  
 
This study is a secondary exploratory analysis of data collected in 2007-2008, as opposed to a new 
study specifically designed and powered to assess the association between anti-malarial drug use and 
health outcomes. We are limited to the datasets available and have not recruited any new participants 
or sourced any new survey responses as part of this project. As such, for some of the comparisons 
presented, the number of respondents who reported taking a specific anti-malarial medication may 
be small, and the comparisons made may have low statistical power to detect a difference in self-
reported health.   
 
The original studies were designed to compare the health of deployed personnel to a comparison 
group of non-deployed personnel. The analyses presented will focus solely on the deployed groups 
who responded to questions regarding anti-malarial drug use on deployment.   
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2. Methods 
2.1 Data sources and analyses 
 
This study uses de-identified data from the Bougainville, Solomon Islands and East Timor Deployment 
Health Studies conducted by the then Centre for Military and Veterans’ Health. The original study 
reports were published in 2009 and are available on the Department of Defence website [18-20].  The 
analysis presented focusses on the deployed groups in each study who completed questions on anti-
malarial drug use.  The original survey response rates in the deployed arm of these studies were 46% 
for East Timor, 49% for Bougainville and 45% for Solomon Islands.   
 
The study surveys were completed in 2007 or 2008, approximately four to ten years after the 
Bougainville deployments, three to seven years after the Solomon Islands deployments that were 
investigated in the study, and two to eight years after the investigated East Timor deployments. 
Questions about anti-malarial drug use, physical and mental health measures and open-ended 
questions were identical across the three studies. 
 
Reported use of anti-malarial drugs 
 
The questions shown in Figure 2 determined who took which antimalarial drugs for their deployment 
and whether they changed from one drug to another. The analysis of reported use is detailed in the 
following section (2.2).  
 
 
Figure 2. Questions in the Bougainville, Solomon Islands and East Timor Health Studies on use of 
anti-malarial drugs on deployment 
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Reactions to anti-malarial drugs 
 
Data were analysed from the participants’ responses to the three survey questions shown in Figure 3.  
 
Q17. Did you have a significant reaction to any vaccinations or medications that you received for your 
deployment? [Tick boxes No; Yes; Don’t know] 
a. Which vaccination(s) or medication(s) did you react to? Please specify [Open-ended text box] 
b. Did you seek medical advice for this reaction? [Tick boxes Yes; No] 
Figure 3. Questions in the Bougainville, Solomon Islands and East Timor Health Studies about 
reactions to health countermeasures  
 
In response to Question 17a, participants either: 
 named a specific vaccination or medication; 
 named a specific vaccination or medication and detailed the reaction; or  
 detailed a reaction but did not name a specific vaccination or medication 
 
Descriptive statistics are presented on the number of respondents who reported a reaction to 
doxycycline, mefloquine and primaquine and the type of reactions that were reported. In this 
question, a ‘significant reaction’ (Figure 3) was not defined in the questionnaire, so respondents 
decided for themselves which reactions were significant.   
 
Use of anti-malarial drugs and mental health outcomes 
 
Mental health outcomes for this analysis are defined as psychological distress as measured by the 
Kessler-10 (K10) and symptoms of post-traumatic stress disorder as measured by the Post-Traumatic 
Stress Disorder Checklist – Civilian Version (PCL-C). The K10 is a 10-item scientifically validated 
instrument designed to produce a measure of an individual’s global level of psychological distress [21]. 
Individuals rate their level of anxiety and depressive symptoms during the preceding four weeks by 
reporting the frequency of each experience on a five-point scale ranging from ‘all of the time’ to ‘none 
of the time’. An example of the questions is ‘About how often did you feel depressed?’ 
 
The PCL-C is a scientifically validated checklist designed to produce a measure of the symptoms of 
PTSD that are identified in the Diagnostic and Statistical Manual of Mental Disorders [22]. Individuals 
rate how much they have been bothered by a problem in the past month by checking a five-point 
Likert scale ranging from ‘not at all’ to ‘extremely’. An example is ‘Trouble falling or staying asleep’. 
While a military version of the PCL is available, the civilian version is more commonly used in research.  
 
Linear regression models were used to compare the mean scale scores of the K10 and PCL-C between 
those who took different types of anti-malarial drugs and those who did not, and between the type of 
anti-malarial drug used ‘mostly’.  When comparing mean scale score we were interested in whether 
there was a statistically significant difference and whether the difference was clinically significant.  
Clinical significance is defined as a change which has a noticeable effect on daily life [23].  In the 
context of treatment of patients, an improvement of over 6.73 points [24] on the K10 scale, and 10 
points on the PCL-C scale [25], have been proposed as clinically significant differences.   
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Logistic regression models were used to compare the proportion who scored above recommended 
screening cut-off scores on the K10 (≥25) and PCL-C (≥29).  In the Health and Wellbeing Study of the 
ADF, a cut-off of 25 on the K10 score corresponded to 30 day ICD-10 affective disorder as measured 
by the Composite International Diagnostic Interview (CIDI), and using a cut-off of 29 on the PCL-C scale 
would detect 79% of cases with ICD-10 PTSD [26].   
 
Use of anti-malarial drugs and physical health outcomes 
 
The 12-Item Short Form Health Survey (SF-12) (Ware et al. 2002) is a 12-item scientifically validated 
survey designed to produce a measure of physical and mental health. The first question, SF-1, is an 
overview question that asks respondents to rate their health, in general, as either excellent; very good; 
good; fair or poor. The percentage who reported their health to be ‘fair’ or ‘poor’ was compared 
between groups who used different anti-malarial drugs, using logistic regression.   
 
A 67 item symptom checklist was adapted from the Australian Gulf War Veteran Health Study [27] and 
the Operation TELIC study of UK Gulf War veterans [28]. Logistic regression was used to compare the 
prevalence of five individual symptoms known to be adverse effects of mefloquine use (sleeping 
difficulties, headaches, distressing dreams, nausea and dizziness) [13]. The mean total number of 
symptoms, reported in the last month, was also compared between exposure groups using negative 
binomial regression models. 
 
All statistical models were adjusted for rank (enlisted or officer), sex, age (20-29, 30-39, 40+) and 
Service (Navy, Army, Air Force). The models which assessed self-reported mental health were also 
adjusted for stressful or combat exposures on deployment.  If a respondent answered yes to one of 
the following events: ‘saw dead bodies’; ‘handled dead bodies’; ‘were witness to human degradation 
and misery on a large scale’; ‘were present when a close friend or co-worker was injured or killed’; or 
‘were present when a loved one was injured or killed’, they were recorded as having a ‘stressful or 
combat exposure’ on deployment.  These self-reported exposures were collected as part of the 
Traumatic Exposure Scale Revised (TSES-R)  [29]. 
 
Open-ended question responses about anti-malarial drugs 
 
Open-ended questions in surveys allow for illustration and understanding of responses to closed-
ended questions and an identification of issues of importance to respondents that were not covered 
in closed-ended questions [30, 31]. Specific open-ended questions about anti-malarial drugs were not 
asked in the CMVH studies. Open-ended questions were asked about ‘reasons for medical care on 
deployment’; ‘positive and negative experiences of deployment’; ‘traumatic events on deployment’; 
‘stressful experiences on deployment’; ‘military experiences or exposures on deployment’; ‘important 
health concerns’ and ‘additional comments’. All responses to the survey open-ended questions were 
read. Thematic analysis (identifying patterns in content) of the responses was performed. Respondent 
quotes presented in the findings were edited to correct spelling, with punctuation the respondent’s 
own. A respondent number is provided next to the quote to allow for verification (the row number of 
the response in an Excel spreadsheet and not the respondent’s study identification number). 
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2.2 Participants 
 
The number of participants who responded to questions about anti-malarial drug use on deployment 
is given in Table 5. The East Timor and Bougainville deployed study groups (n=1519 and n=1884 
respectively) were considerably larger than in the Solomon Islands study (n=205).  Approximately 3% 
in each deployment location reported that they did not use anti-malarial drugs.  The percentage of 
respondents who reported that they changed the anti-malarial drug they were using was 
approximately 5% in East Timor and Bougainville.  In all three deployment locations over 80% reported 
that they took their anti-malarial drugs ‘all of the time’.   
 
Table 5: Use of anti-malarial drugs on each deployment 
 East Timor n (%) Bougainville n (%) Solomon Islands n (%) 
Used anti-malarial drugs on deployment 
Yes 1435 (94.5) 1767 (93.8)  198 (96.6) 
No 50 (3.3) 64 (3.4) 6 (2.9) 
Don’t know 34 (2.2) 53 (2.8) 1 (0.5) 
Changed anti-malarial drug 
Yes 55 (5.5) 65 (4.8) 2 (1.1) 
No 946 (94.5) 1282 (95.2) 175 (98.9) 
Answer not available 434 420 22 
Took anti-malarial drugs 
All of the time 852 (85.7) 1188 (88.2) 147 (83.1) 
Most of the time 107 (10.8)  105 (7.8) 20 (11.3) 
Some of the time 26 (2.6) 37 (2.7) 3 (1.7) 
Rarely or never 9 (0.9) 17 (1.3) 7 (4.0) 
Answer not available 441 420 22 
 
Table 6 reports the number of respondents who reported using each of the anti-malarial drugs on the 
three deployments.  These totals included the drug they used ‘mostly’ and drugs respondents used if 
they had to change their medication.  In total, 66 of the respondents reported mefloquine use in East 
Timor and 27 reported using mefloquine in Bougainville.  Of the 27 who used mefloquine in 
Bougainville, 10 (37.0%) had changed to mefloquine after using doxycycline. Of the 66 who used 
mefloquine in East Timor, 19 (28.8%) had changed to mefloquine after using doxycycline.  
 
Only descriptive findings will be presented from the Solomon Islands Health Study as the number of 
members who reported use of mefloquine in this study was too low to permit inferential analysis 
(n=5). 
 
Table 6: Anti-malarial drugs used on deployment 
 East Timor 
(n=1058) 
Bougainville 
(n=1432) 
Solomon Islands1 
(n=205) 
Doxycycline 895 (84.6%) 1257 (87.8%) 163 (79.5%) 
Mefloquine 66 (6.2%) 27 (1.9%) 5 (2.4%) 
Malarone 7 (0.7%) 12 (0.8%) 0 
Others 14 (1.3%) 20 (1.4%) 1 (0.5%) 
1 32/205 did not provide a response to ‘which anti-malarial drug they used ‘mostly’’ 
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Primaquine use was reported by approximately 70% of respondents in each of the three surveys (Table 
7).  Between 10% and 17% did not know whether or not they had used primaquine.  Ninety-one per 
cent of East Timor and Bougainville veterans reported that they took primaquine as directed.   
 
Table 7: Use of primaquine on each deployment 
 East Timor n (%) Bougainville n (%) Solomon Islands n (%) 
Used primaquine       
Yes 1018 (67.2) 1284 (68.6) 143 (70.4) 
No 237 (15.6) 301 (16.1) 39 (19.2) 
Don’t know 260 (17.2) 288 (15.4) 21 (10.3) 
Took primaquine       
As directed 648 (91.0) 876 (91.0) 115 (82.7) 
Most of the time 49 (6.9) 67 (7.0) 15 (10.8) 
Some of the time 8 (1.1) 11 (1.1) 4 (2.8) 
Rarely or never 7 (1.0) 9 (0.9) 5 (3.5) 
Answer not available 306  321  64  
 
One of the primary comparisons in this report is between those who used doxycycline and those 
who used mefloquine on deployment.  In Table 8, we compare the demographic characteristics of 
those who took each medication.  The statistical models used adjusted for demographic differences 
between these group by including age, sex, service and rank as independent predictors.   
 
Table 8: Demographic characteristics of respondents who used mefloquine and doxycycline1 
 East Timor  Bougainville  
 Doxycycline Mefloquine  Doxycycline Mefloquine  
Age at survey     
20-29 110 (12.3%) 14 (21.2%) 74 (5.9%) 1 (3.7%) 
30-39 432 (48.3%) 33 (50.0%) 552 (43.9%) 12 (44.4%) 
40+ 353 (39.4%) 19 (28.8%) 631 (50.2%) 14 (51.9%) 
Sex     
Male 792 (88.5%) 58 (87.9%) 1094 (87.0%) 24 (88.9%) 
Female 103 (11.5%) 8 (12.1%) 163 (13.0%) 3 (11.1%) 
Service     
Navy 79 (8.8%) 1 (1.5%) 218 (17.3%) 3 (11.1%) 
Army 721 (80.6%) 63 (95.5%) 974 (77.5%) 24 (88.9%) 
RAAF 95 (10.6%) 2 (3.0%) 65 (5.2%) 0 
Rank     
Officer 242 (27.0%) 11 (16.7%) 447 (35.6%) 13 (48.1%) 
Enlisted 653 (73.0%) 55 (83.3%) 810 (64.4%) 14 (51.9%) 
ADF Employment      
Active 749 (83.7%) 56 (84.8%) 1081 (86.0%) 25 (92.6%) 
Terminated 146 (16.3%) 10 (15.2%) 176 (14.0%) 2 (7.4%) 
Total 895 66 1257 27 
1 Demographics measured at the time of survey response 
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3. Results 
3.1 Self-reported reactions to anti-malarial drugs on deployment 
 
In both East Timor and Bougainville, ‘significant reactions’ to mefloquine were more frequently 
reported than ‘significant reactions’ to doxycycline (19.7% v 5.0%, p=0.0001 and 11.1% v 4.1%, p=0.11) 
(Table 9). Among those who reported taking primaquine, fewer than two per cent reported a 
significant reaction to this drug.  
 
Table 9: Self-reported significant reactions to medications received on deployment 
 East Timor Bougainville 
Reported significant reactions to:   
Doxycycline 45/897 (5.0%) 52/1257 (4.1%) 
Mefloquine 13/66 (19.7%) 3/27 (11.1%) 
Primaquine 19/1020 (1.9%) 20/1284 (1.6%) 
 
The types of reactions that respondents associated with their use of anti-malarial drugs are shown in 
Table 10. Some respondents reported more than one type of reaction and some detailed the duration 
of their reaction. The majority of respondents sought medical advice for their reaction (doxycycline 
64%; mefloquine 62.5%; primaquine 56.4%). 
 
Table 10: Number of respondents who reported a significant reaction to anti-malarial drugs on 
Bougainville or East Timor deployments and number of particular reactions 
Doxycycline n=971 Mefloquine n=16 Primaquine n=39 
Reaction term Cases2 Reaction term Cases Reaction term Cases3 
No description 50 No description 10 No description 22 
Photosensitivity 20 Nightmares 3 Nausea/feeling ‘ill’ 7 
Abdominal pain 7 Disturbed sleep 2 Vomiting 4 
Vivid dreams 7 Abdominal pain 1 Diarrhoea 2 
Heartburn/reflux 6 Motion sickness 1 Fever 2 
Nausea 5 Late-onset overheating 1 Nightmares 2 
Diarrhoea 3     
Dizziness 2     
Vision problems 2     
Vomiting 2     
1 Another 14 respondents reported that they reacted to doxycycline, however they had not answered the 
questions about anti-malarial use. Reactions these respondents reported were diarrhoea, abdominal pain, 
nausea, prickly heat, shortness of breath, erratic heart beats. One Bougainville Health Study respondent 
stated: “Doxycycline. We were taking in excess of the recommended dosage and it caused night sweats, vivid 
dreams and melancholia, bursting into tears for no reason” (R1894). 
2 1 case each of aches, amenorrhea, cough, fever, hallucinations, lethargy, lowered immunity, sore gums. 
3 1 case each of anger, dizziness, flushes, headaches, mouth ulcers, shingles, ulcer. 
 
Two respondents reported a reaction to other anti-malarial drugs. One respondent who reported that 
they took chloroquine, doxycycline and primaquine stated that chloroquine gave them an upset 
stomach. One respondent who conveyed that they were “involved in the Primaquine/Etaquine [an 
earlier name for tafenoquine] anti-malarial study” (R1773), said that etaquine caused them 
substantial stomach cramping.  
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Thirty-six respondents detailed a reaction to an anti-malarial drug but did not name which drug they 
thought was associated with their reaction. Twenty of these respondents reported use of primaquine, 
18 doxycycline, five mefloquine, one Malarone (atovaquone/proguanil) and five unspecified anti-
malarial drugs.  
 
Of these thirty-six, 14 respondents reported that they reacted to ‘malarial pills/trial malaria drug’, i.e. 
they did not name a specific anti-malarial drug.  These reactions reported included eight cases of vivid 
dreams, four of nausea, four of photosensitivity, four of aggression, and one case each of abdominal 
pain, blurring of peripheral vision, calcium deposits in eyes, diarrhoea, headaches, indigestion, 
intolerance to shellfish, migraines, lethargy and loss of appetite. 
 
3.2 Associations between use of anti-malarial drugs and mental health outcomes 
 
Mefloquine 
 
East Timor  
 
East Timor veterans who used mefloquine reported a mean K10 score 2.1 points higher than those 
who did not (Table 11).  While this difference was statistically significant (p=0.04) a two-point 
difference in K10 scores is not considered to be clinically significant.  Similarly, East Timor veterans 
who used ‘mostly’ mefloquine had a K10 score 3.3 points higher (p=0.004) compared to respondents 
who ‘mostly’ used doxycycline (Table 12).  Assessing the proportion who scored ≥25 on the K10 scale, 
those who used ‘mostly’ mefloquine were more likely to score above this cut-off compared to the 
‘mostly’ doxycycline group (OR 1.99 (1.01, 3.95), p=0.05) (Table 12).   
 
In contrast, there was no evidence of an association between mefloquine use and PCL-C scores in East 
Timor veterans (Tables 11 and 12).   
 
Table 11: K10 and PCL-C scores in mefloquine users in East Timor 
K10 N Mean (SD) Adj. Difference  
95% CI 
p-
value 
N K10 ≥ 25 
n (%) 
Adj. Odds Ratio 
95% CI 
p-
value 
Used 
mefloquine 
65 19.6 (9.9) 2.10 (0.10, 4.05) 0.04 65 15 (23.1) 1.60 (0.86, 2.99) 0.14 
Did not use 
mefloquine 
964 17.3 (7.5) 0 (Reference)  977 157 (16.1) 1 (Reference)  
PCL-C N Mean (SD) Adj. Difference  
95% CI 
p-
value 
N PCL-C ≥ 29 
n (%) 
Adj. Odds Ratio 
95% CI 
p-
value 
Used 
mefloquine 
57 29.4 (13.9) 0.77 (-2.65, 4.20) 0.66 62 23 (37.1) 1.17 (0.67, 2.05) 0.57 
Did not use 
mefloquine 
940 27.9 (12.4) 0 (Reference)  963 308 (32.0) 1 (Reference)  
1 Adjusted for combat exposure, rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service.   
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Table 12: K10 and PCL-C scores and anti-malarial drug used ‘mostly’ in East Timor 
K10 N Mean (SD) Adj. Difference  
95% CI 
p-
value 
N K10 ≥ 25 
n (%) 
Adj. Odds Ratio 
95% CI 
p-
value 
Doxycycline 868 17.3 (7.5) 0 (Reference)  880 144 (16.4) 1 (Reference)  
Mefloquine 47 20.9 (10.7) 3.30 (1.06, 5.54) 0.004 47 13 (27.7) 1.99 (1.01, 3.95) 0.05 
Malarone 3 17.7 (8.1) 0.97 (-7.57, 9.52) 0.82 3 1 (33.3) 3.03 (0.27, 34.48) 0.37 
Other 12 21.3 (9.3) 3.21 (-1.09, 7.51) 0.14 12 4 (33.3) 2.17 (0.63, 7.47) 0.22 
Don’t know 57 14.9 (5.7) -2.46 (-4.76, -0.16) 0.04 54 3 (5.6) 0.32 (0.09, 1.09) 0.07 
PCL-C N Mean (SD) Adj. Difference  
95% CI 
p-
value 
N PCL-C ≥ 29  
n (%) 
Adj. Odds Ratio 
95% CI 
p-
value 
Doxycycline 845 28.0 (12.6) 0 (Reference)  868 279 (32.1) 1 (Reference)  
Mefloquine 41 30.0 (13.4) 1.10 (-2.85, 5.05) 0.58 44 18 (40.9) 1.33 (0.70, 2.53) 0.38 
Malarone 3 28.3 (12.7) 1.08 (-13.00, 15.17) 0.88 3 1 (33.3) 1.13 (0.10, 12.81) 0.92 
Other 11 39.5 (19.1) 10.82 (3.41, 18.21) 0.004 11 6 (54.6) 2.25 (0.67, 7.58) 0.19 
Don’t know 56 23.8 (8.6) -4.92 (-8.68, -1.17) 0.01 56 11 (19.6) 0.51 (0.24, 1.05) 0.07 
Adjusted for combat exposure, rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service.   
 
Bougainville 
 
In Bougainville veterans the mean K10 score was 2.6 points higher in the group who used mefloquine, 
compared to the group who did not. This result was not statistically significant (p=0.07) (Table 13).  
 
Table 13: K10 and PCL-C scores in mefloquine users in Bougainville 
K10 N Mean (SD) Adj. Difference  
95% CI 
p-
value 
N K10 ≥ 25 
n (%) 
Adj. Odds Ratio 
95% CI 
p-
value 
Used 
mefloquine 
26 19.7 (7.5) 2.56 (-0.25, 5.37) 0.07 26 4 (15.4) 1.37 (0.46, 4.12) 0.58 
Did not use 
mefloquine 
1349 16.7 (7.0) 0 (Reference)  1366 166 (12.2) 1 (Reference)  
PCL-C N Mean (SD) Adj. Difference  
95% CI 
p-
value 
N PCL-C ≥ 29  
n (%) 
Adj. Odds Ratio 
95% CI 
p-
value 
Used 
mefloquine 
23 32.2 (13.6) 3.81 (-0.89, 6.20) 0.11 23 14 (60.9) 3.20 (1.33, 7.70) 0.01 
Did not use 
mefloquine 
1301 26.6 (11.2) 0 (Reference)  1335 392 (29.4) 1 (Reference)  
Adjusted for combat exposure, rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service.   
 
Respondents who used mefloquine ‘mostly’ also reported a K10 score 4.1 points higher than members 
who ‘mostly’ used doxycycline (95% CI (0.44, 7.80), p=0.03). Members who used mefloquine ‘mostly’ 
had greater odds of scoring above 25 on the K10 scale (OR=3.13 (0.95, 10.36)), than those who used 
doxycycline, although this result was not statistically significant (p=0.06) (Table 14).   
 
Bougainville veterans who used mefloquine ‘mostly’ reported higher PCL-C scores than the 
doxycycline group indicated by higher mean scores (6.43 95% CI (0.35, 12.50), p=0.03) and greater 
odds of scoring above the threshold of 29 (OR, 95% CI 3.73 (1.18, 11.80), p=0.03) (Table 14).  
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Table 14: K10 and PCL-C scores and anti-malarial drug used ‘mostly’ in Bougainville 
K10 N Mean (SD) Adj. Difference  
95% CI1 
p-
value 
N K10 ≥ 25 
n (%) 
Adj. Odds Ratio 
95% CI1 
p-
value 
Doxycycline 1198 16.7 (6.9) 0 (Reference)  1213 140 (11.5) 1 (Reference)  
Mefloquine 16 21.0 (8.8) 4.12 (0.44, 7.80) 0.03 16 4 (25.0) 3.13 (0.95, 10.36) 0.06 
Malarone 9 17.4 (8.6) 1.26 (-3.33, 5.84) 0.59 10 2 (20.0) 2.06 (0.43, 9.90) 0.37 
Other 14 16.9 (10.3) 0.17 (-3.51, 3.86) 0.93 14 2 (14.3) 1.35 (0.29, 6.17) 0.70 
Don’t know 79 17.2 (7.7) 0.40 (-1.27, 2.08) 0.64 79 13 (16.5) 1.63 (0.84, 3.16) 0.15 
PCL-C N Mean (SD) Adj. Difference  
95% CI1 
p-
value 
N PCL-C ≥ 29  
n (%) 
Adj. Odds Ratio 
95% CI1 
p-
value 
Doxycycline 1155 26.6 (11.2) 0 (Reference)  1186 350 (29.5) 1 (Reference)  
Mefloquine 14 34.9 (16.0) 6.43 (0.35, 12.50) 0.03 14 9 (64.3) 3.73 (1.18, 11.80) 0.03 
Malarone 10 28.4 (11.7) 2.25 (-4.67, 9.17) 0.52 10 4 (40.0) 1.91 (0.52, 7.01) 0.33 
Other 12 23.3 (6.8) -3.01 (-9.33, 3.32) 0.35 12 2 (16.7) 0.50 (0.11, 2.36) 0.38 
Don’t know 75 27.9 (12.6) 1.44 (-1.30, 4.19) 0.30 77 25 (32.5) 1.16 (0.68, 1.97) 0.59 
Adjusted for combat exposure, rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service 
 
Primaquine 
 
There was no evidence of an association between self-reported primaquine use and symptoms of 
psychological distress or PTSD in either the Bougainville or East Timor studies.  Bougainville veterans 
who used primaquine were less likely to score above 25 on the K10 scale (p=0.01), compared to those 
who did not, however, this result was not replicated in East Timor veterans (Tables 15 and 16). 
 
Table 15: Primaquine use and K10 scores1 
East Timor Did not use primaquine Used primaquine ‘Did not know’ 
N 229 992 257 
Mean (SD) 17.2 (7.2) 17.3 (7.6) 17.4 (7.6) 
Adj Difference 95% CI 0 (Reference) -0.46 (-1.64, 0.73) -0.18 (-1.54, 1.18) 
p-value  0.45 0.79 
N 232 1001 259 
K10 ≥ 25 n (%) 38 (16.4) 148 (14.8) 39 (15.1) 
Adj OR 95% CI 1 (Reference) 0.82 (0.53, 1.28) 0.88 (0.53, 1.48) 
p-value  0.38 0.64 
Bougainville Did not use primaquine Used primaquine ‘Did not know’ 
N 291 1230 277 
Mean (SD) 17.0 (6.7) 16.5 (6.7) 17.1 (7.4) 
Adj Difference 95% CI 0 (Reference) -0.51 (-1.48, 0.47) 0.09 (-1.06, 1.23) 
p-value  0.31 0.88 
N 293 1249 281 
K10 ≥ 25 n (%) 45 (15.4) 136 (10.9) 37 (13.2) 
Adj OR 95% CI 1 (Reference) 0.60 (0.40, 0.90) 0.84 (0.52, 1.36) 
p-value  0.01 0.47 
1Adjusted for combat exposure, rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service.   
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Table 16: Primaquine use and PCL-C scores1 
East Timor Did not use primaquine Used primaquine ‘Do not know’ 
N 226 955 245 
Mean (SD) 27.9 (12.8) 27.3 (11.9) 28.2 (12.8) 
Adj Difference 95% CI 0 (Reference) -1.40 (-3.38, 0.57) -0.39 (-2.66, 1.88) 
p-value  0.16 0.74 
N 227 998 256 
PCL-C ≥ 29 n (%) 70 (30.8) 304 (30.8) 88 (34.4) 
Adj OR 95% CI 1 (Reference) 0.89 (0.62, 1.27) 1.08 (0.72, 1.62) 
p-value  0.51 0.72 
Bougainville Did not use primaquine Used primaquine ‘Do not know’ 
N 277 1186 269 
Mean (SD) 27.0 (11.3) 26.5 (10.9) 26.7 (11.7) 
Adj Difference 95% CI 0 (Reference) -0.81 (-2.42, 0.80) -0.23 (-2.11, 1.65) 
p-value  0.32 0.81 
N 286 1223 275 
PCL-C ≥ 29 n (%) 85 (29.7) 363 (29.7) 81 (29.5) 
Adj OR 95% CI 1 (Reference) 0.97 (0.71, 1.34) 0.96 (0.66, 1.40) 
p-value  0.87 0.84 
1 Adjusted for combat exposure, rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service. 
 
3.4 Associations between use of anti-malarial drugs and physical health outcomes 
 
Mefloquine 
 
Veterans who used mefloquine on deployment in East Timor or Bougainville were slightly more likely 
to report ‘fair or poor’ general health compared to those who did not.  However, these results were 
not statistically significant (Table 17).   
 
Table 17: Mefloquine use and ‘fair or poor’ general health 
 n Fair or Poor health n (%)1 OR 95% CI1 p-value 
East Timor     
Did not use mefloquine 928 199 (21.4) 1 (Reference)  
Used mefloquine 64 17 (26.6) 1.37 (0.76, 2.49) 0.30 
Bougainville     
Did not use mefloquine 1296 233 (18.0) 1 (Reference)  
Used mefloquine 26 7 (26.9) 1.80 (0.74, 4.39) 0.19 
1 Adjusted for rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service. 
 
Veterans who used mefloquine ‘mostly’ on deployment in Bougainville were more likely to report 
‘fair or poor’ general health compared to those who used doxycycline.  No association between 
‘mostly’ mefloquine use and poor general health was observed in the East Timor study (Table 18).   
 
  
 20 
 
Table 18: Anti-malarial used mostly and ‘fair or poor’ general health 
 n Fair or Poor health n (%)1 OR 95% CI1 p-value 
East Timor     
Doxycycline 878 187 (21.3) 1 (Reference)  
Mefloquine 46 13 (28.3) 1.49 (0.76, 2.94) 0.25 
Malarone 3 0 (0)   
Other 12 7 (58.3) 4.43 (1.36, 14.44) 0.01 
Don’t know 56 9 (16.1) 0.45 (0.20, 0.99) 0.05 
Bougainville     
Doxycycline 1208 209 (17.3) 1 (Reference)  
Mefloquine 16 6 (37.5) 3.13 (1.11, 8.85) 0.03 
Malarone 10 3 (30.0) 2.33 (0.59, 9.28) 0.23 
Other 13 2 (15.4) 0.79 (0.17, 3.61) 0.76 
Don’t know 79 21 (26.6) 1.54 (0.89, 2.68) 0.13 
1 Adjusted for rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service. 
 
Veterans who used mefloquine in Bougainville reported more health symptoms than Bougainville 
veterans who did not use mefloquine (Table 19).  There was no association between mefloquine use 
and the mean number of health symptoms reported in East Timor veterans.   
 
Table 19: Mefloquine use and mean number of health symptoms reported  
n Mean (Std) Adjusted ratio of means (95% CI)1 p-value 
East Timor     
Did not use mefloquine 938 15.6 (12.4) 1 (Reference)  
Used mefloquine 65 16.8 (13.0) 1.05 (0.85, 1.30) 0.63 
Bougainville     
Did not use mefloquine 1328 14.7 (11.7) 1 (Reference)  
Used mefloquine 27 21.7 (14.2) 1.47 (1.07, 2.04) 0.02 
1 Adjusted for rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service. 
 
Consistent with the results from Table 19, the prevalence of individual health symptoms reported in 
the previous month was higher in Bougainville veterans who used mefloquine on deployment, 
compared to those who did not take mefloquine (Figure 4).  However, this pattern of reporting more 
symptoms was not observed in East Timor veterans (Figure 5).    
 
In assessing five symptoms known to be common side-effects of mefloquine use (see Table 3), almost 
all of these individual symptoms were not significantly higher among mefloquine users.  The exception 
was ‘distressing dreams’ which was reported more frequently in Bougainville veterans who used 
mefloquine (Table 20).   
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Figure 4:  Health symptoms in Bougainville veterans by mefloquine use 
 
 
Figure 5:  Health symptoms in East Timor veterans by mefloquine use 
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Table 20: Comparison of selected symptoms by mefloquine use 
 East Timor Bougainville 
 Mefloquine 
(n=65) 
Non-mefloquine Mefloquine 
(n=27) 
Non-mefloquine 
(n=1392) 
Symptom n (%) n (%) OR 95% CI1 n (%) n (%) OR 95% CI1 
Sleeping 
difficulties 
 
39 (60.0) 596 (60.3) 1.02 (0.60, 1.72) 20 (74.7) 837 (60.1) 1.99 (0.83, 4.77) 
Headaches 
 
35 (53.8) 516 (52.2) 1.06 (0.63, 1.76) 14 (51.9) 719 (51.7) 1.10 (0.51, 2.38) 
Distressing 
dreams 
 
19 (29.2) 280 (28.3) 0.99 (0.56, 1.73) 14 (51.9) 332 (23.9) 3.45 (1.60, 7.44) 
Nausea 
 
11 (16.9) 113 (11.4) 1.64 (0.82, 3.27) 5 (18.5) 158 (11.4) 1.92 (0.71, 5.20) 
Dizziness, 
fainting or 
blackouts 
11 (16.9) 117 (11.8) 1.42 (0.71, 2.83) 4 (14.8) 159 (11.4) 1.46 (0.49, 4.33) 
1 Adjusted for rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service. 
 
Primaquine 
 
There was no association between primaquine use and poorer general health or increased symptom 
reporting in either Bougainville or East Timor veterans (Table 21 and 22).   
 
Table 21: Primaquine use and ‘fair or poor’ general health  
n Fair or Poor health n (%) OR 95% CI1 p-value 
East Timor     
Did not use primaquine 234 41 (17.5) 1 (Reference)  
Used primaquine 999 199 (19.9) 1.42 (0.94, 2.15) 0.09 
Do not know 255 71 (27.8) 1.80 (1.15, 2.82) 0.01 
Bougainville     
Did not use primaquine 292 59 (20.2) 1 (Reference)  
Used primaquine 1242 216 (17.4) 0.94 (0.66, 1.33) 0.71 
Do not know 282 58 (20.6) 0.97 (0.65, 1.47) 0.90 
1 Adjusted for rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service. 
 
Table 22: Primaquine use and mean number of health symptoms reported  
n Mean (Std) Adjusted ratio of means 
(95% CI)1 
p-value 
East Timor     
Did not use primaquine 236 14.5 (12.0) 1 (Reference)  
Used primaquine 1012 15.3 (12.0) 1.05 (0.92, 1.19) 0.49 
Do not know 259 16.2 (12.6) 1.08 (0.93, 1.25) 0.34 
Bougainville     
Did not use primaquine 297 14.2 (12.2) 1 (Reference)  
Used primaquine 1272 14.6 (11.5) 1.04 (0.92, 1,17) 0.52 
Do not know 286 15.2 (12.2) 1.05 (0.91, 1.21) 0.54 
1 Adjusted for rank (enlisted v officer), sex, age (20-29, 30-39, 40+) and Service.  
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3.5 Open-ended question responses about anti-malarial drugs 
 
Six open-ended questions, shown in Figure 6, contained responses about anti-malarial drugs. 
 
Q22. Did you spend one or more nights under medical care during this deployment? If yes, please 
explain why. 
Q33. During the deployment, what do you consider to have been the major NEGATIVE experiences? 
Q42. Please list any other stressful experiences and fill in which best describes how much stress it 
caused (3 open-ended fields provided) 
Q48. Are there other important military experiences or exposures we have not asked you about? If 
yes, please give details in the space provided here. 
Q49. Are there other important health concerns we have not asked you about? If yes, please give 
details in the space provided here. 
Q50. Do you have any additional comments you would like to add? If yes, please give details in the 
space provided here or on additional pages. 
Figure 6. Open-ended questions in the Bougainville and East Timor Health Studies that contained 
responses about anti-malarial drugs 
 
Thirty East Timor Health Study respondents and 27 Bougainville Health Study respondents made at 
least one response about anti-malarial drugs in the open-ended questions. The majority of these 
responses were negative about the experience of taking these drugs. One respondent, however, 
provided a positive response and one provided a neutral response (both about the anti-malarial drug 
trials).  Concerning mefloquine and the drug trials that tested mefloquine, 16 respondents conveyed 
a negative response. Of these 16, six had reported that they took mefloquine, while 10 took other 
drugs or did not know or answer which drugs they took. 
 
Overall, most of the respondents were concerned with the effect of long-term use of doxycycline and 
whether symptoms they experienced post-deployment (resolved or ongoing) were related to the use 
of this drug.  
 
Reason for medical care (n=6) 
Three respondents reported spending time in medical care for a reaction to doxycycline. One 
respondent reported “a bad allergic reaction” with vomiting and indigestion, one had abdominal 
cramps and one had irregular heartbeats. One respondent conveyed that mefloquine caused them 
“bad sleeping, massive mood shifts, altered conscious states” (R749), while two respondents noted 
that anti-malarial drugs made them sick (reflux and vomiting, dizziness). 
 
Negative experiences (n=8) 
Of six respondents who took doxycycline, three noted that it made them prone to sunburn and had 
effects on their eyesight. One felt this was a long term effect: “…the side effects that I have been left 
with…eyesight has deteriorated ever since Bougainville” (R647). Two of the six just conveyed that 
taking the pills was a negative experience, while one believed that their suspected case of Crohn’s 
Disease was caused by the drug. Two respondents who took mefloquine stated this fact as a negative 
experience, with one writing: “LARIUM!!!” [The trade name for mefloquine] (R749) and the other: 
“Trial drugs” (R1050).  
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Stressful experiences (n=2) 
Respondents R647 and R749 provided similar comments here as they did in the negative experiences 
questions. 
 
Other military experiences/exposures (n=4) 
Two respondents, both of whom didn’t answer the question about which anti-malarial prophylaxis 
they took, stated that questions about the anti-malarial drug trials weren’t asked in the survey, with 
one writing: “Mefloquine anti-malarial drug effects” (R633).  
 
One respondent was confused, erroneously, about why they had been taking primaquine when in 
later deployments ‘Primaquine was trialled’ (tafenoquine was the trial drug, with primaquine the 
standard post-exposure prophylaxis as comparator), while another enjoyed the tafenoquine trial and 
hoped for its success over the “complicated Primaquine” (R123). 
 
Other health concerns (n=31) 
Fifteen respondents who took doxycycline discussed its impact on health post-deployment. Five 
respondents questioned ‘effects of long-term use of Doxycycline’ without elaboration.  
 
Five believed the drug damaged their eyes, with one respondent (who also took mefloquine) stating: 
“A study on repercussion of malarial drugs on eyesight should be carried out (R1840)”. Two 
respondents felt that doxycycline damaged or had effects on their stomach, one said it caused them 
long-term sunburn sensitivity, one associated it with unexplained weight gain, and one who developed 
allergic reactions three years after their Bougainville deployment: “was told that this could have been 
caused by being on Doxy” (R1446).  
 
Four respondents commented negatively on the mefloquine trials–two of these took mefloquine, one 
took doxycycline and one did not answer the prophylaxis question. Of those who took mefloquine, 
one associated the anger he felt after his deployment with the drug and noted that it: “took a while 
to calm down from this” (R1046), while the other questioned side effects: “Trial drugs we were on – 
we were told there are no side effects – had problems with bowels and eyes and military say it’s not 
from trial drugs” (R1050). The respondent who took doxycycline wanted to know what happened to 
those given ‘’faulty tablets’’ (R441) in the trial, while the respondent who did not answer the 
prophylaxis question felt questions should have been asked about trial side effects: 
 
The questionnaire never addressed using Larium or Mefloquine to treat Malaria in East 
Timor, or if I experienced any side effects. Considering all the people I have heard with side 
effects, I think it’s a large problem to be left out and possibly it was excluded because the 
Army does not want to accept liability (R284).  
 
Four respondents (1 doxycycline, 1 mefloquine, 2 prophylaxis questions not answered) just stated the 
anti-malarial trials as an additional health concern, without elaboration, e.g.: “Participant in drug trials 
while deployed” (R1404).  
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Two respondents specifically discussed primaquine. One stated that they had: “Primaquine induced 
Hepatitis” (R1495), while the other questioned if it was primaquine that made them sick with 
appendicitis-like symptoms post-deployment. Of two respondents who took doxycycline but not 
primaquine in Bougainville, one stated that they had no problems from the tafenoquine trial, while 
the other stated: “I believe I have side effects from the antimalaria tablets, I have not taken any action 
to date but will in the near future” (R805). 
 
Two respondents mentioned short-term adverse effects from doxycycline, ‘dreams’ in one case, with 
the other a: “stomach ulcer due to taking doxy without adequate food whilst on patrol” (R410).  
 
One respondent who had bouts of dizziness and ‘minor stroke-like symptoms’ post-deployment was 
uncomfortable with Defence Medical’s response that these symptoms: “must have been [their] body's 
reaction to coming off” (R600) doxycycline and primaquine. One respondent who did not answer the 
prophylaxis question but took primaquine stated: “consequences of long term antimalarial therapy 
(R715)” as an additional health concern.  
 
Additional comments (n=7): 
Three respondents who took doxycycline and primaquine wondered about the long-term effect of 
these drugs. One wondered if these drugs were associated with a liver tumour they developed, while 
another with ongoing issues with Irritable Bowel Syndrome post-deployment wondered if doxycycline 
was related to long-term digestion issues. The remaining respondent, who noted a PTSD diagnosis, 
believed: “long time use of doxy must have a detrimental effect on health” (R172).  
 
Respondent R749 who stated that mefloquine was a negative and stressful experience of their 
deployment, expanded on this further here: “LARIAM PROVED A DISASTER IN MANY RESPECTS TO MY 
LIFE! (R749)”. Two other respondents, one who took mefloquine and one who did not answer the 
prophylaxis question felt that there was ‘not enough information given about anti-malarial drug side 
effects’. The final respondent (didn’t know which prophylaxis taken), was confused about the outcome 
of the mefloquine trials and wondered if the ‘trial pill did not work’ or “worked but was too expensive 
for the government” (R1089). 
 
3.6 Descriptive findings from the Solomon Islands Health Study 
 
Two respondents reported that mefloquine was the anti-malarial prophylaxis drug they mostly used 
during their Solomon Islands deployment/s. One respondent changed from using doxycycline during 
their deployment to mefloquine as they were found to be ‘allergic to doxycycline’ (respondent’s 
wording). 
 
Twenty-four respondents reported a reaction to an anti-malarial drug on deployment–20 reactions 
were to doxycycline, two were to primaquine, one was to mefloquine and one respondent reported a 
reaction to both doxycycline and primaquine. Six respondents who reported a reaction to doxycycline 
detailed their reaction and this comprised four instances of ‘Doxy dreams’, one instance of a severe 
sore stomach and diarrhoea and one instance of tender lymph nodes in the neck. Two respondents 
detailed their reaction to primaquine and these both comprised upset stomachs/diarrhoea. The 
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respondent who reported a reaction to mefloquine detailed their reaction as: “Suspected cause for 
sleeplessness (MO [medical officer] diagnosis) and cause for heightened aggression now (perceived by 
self)” (R64). Thirteen of the 24 respondents (54.2%) who reported a reaction to an anti-malarial drug 
sought medical attention for their reaction. 
 
Three participants provided a response about anti-malarial drugs in the survey’s open-ended 
questions. One respondent who took doxycycline but not primaquine said that anti-malarial 
medication gave them bad mood swings. This comment was provided in the negative experiences of 
deployment question. One respondent who took doxycycline discussed their experience with this drug 
in the traumatic events question. They noted while ‘’there has been no lasting effect”, they felt that 
periods of melancholia and ‘acid dreams’ were side effects of taking the drug. 
 
One respondent who reported that mefloquine was the anti-malarial prophylaxis drug that they 
mostly used, discussed their concerns about this drug in the additional comments question. Their 
comment was:   
I had no further follow-up initiated or concern raised by Medical Pers [personnel] in relation 
to issues I experienced (sleeplessness and anxiety) suspected to be side effect from the 
"Larium" anti-malarial drug. I don’t know if anything was ever written on my Med Docs 
[medical documents] by the Deployment MO [medical officer] to raise concern or whether 
ADF is still utilising this drug following concerns by Army Pers [personnel] a couple of years 
[ago] who were placed on a trial program to utilise "Larium" and raised a group concern for 
the side effects experienced (R64). 
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4. Discussion 
4.1 Summary of findings  
 
1. Did deployed veterans who reported taking mefloquine during their deployment have different 
rates of mental health outcomes compared to veterans who reported taking Doxycycline, or other 
anti-malarial drugs? 
 
Yes, there is some evidence that veterans who took mefloquine reported poorer mental health 
outcomes than those that did not, however the findings were below the level of clinical significance 
and are based on small numbers of personnel who reported taking mefloquine. 
 
2. Did deployed veterans who reported taking mefloquine during their deployment have different 
rates of general health outcomes compared to veterans who reported taking doxycycline, or other 
anti-malarial drugs? 
 
Yes, Bougainville veterans who took mefloquine reported more physical health symptoms than those 
who did not. The group who used mefloquine ‘mostly’ in Bougainville were also more likely to report 
‘fair or poor’ general health than those who used doxycycline. These findings were based on a small 
number of veterans in the mefloquine group (n=27 and n=16 respectively). Among East Timor veterans 
there was no association between mefloquine use and the mean number of physical health symptoms 
reported or perceived general health.   
 
3&4. Did deployed veterans who reported taking primaquine on return to Australia have different 
rates of mental/general health outcomes compared to veterans who reported they did not take 
primaquine on return to Australia? 
 
No, there is no evidence that veterans who took primaquine had different rates of mental or general 
health outcomes than those who did not take primaquine.  
 
5. Did deployed veterans report a significant reaction to anti-malarial drugs received during their 
deployment? 
 
Yes, across the East Timor and Bougainville deployments, 4.5% of doxycycline users reported a 
reaction to doxycycline, 17.2% of mefloquine users reported a reaction to mefloquine, and 1.7% of 
primaquine users a reaction to primaquine. The reactions reported were consistent with the reactions 
reported from populaton surveillance sources. 
 
6. Did deployed veterans mention previous use of anti-malarial drugs as an area of concern in 
response to open-ended questions, and what was the nature of responses? 
 
Yes, across the East Timor and Bougainville deployments, a small number of veterans (1.6%, 57 out of 
3,338 study responses) mentioned use of anti-malarial drugs as an area of concern in response to 
open-ended questions. Most respondents were concerned about the health effects of long-term use 
of doxycycline. Approximately a quarter of these respondents (n=16) provided responses that were 
negative about mefloquine or the anti-malarial drug trials. 
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4.2 Interpretation of findings  
 
‘Significant reactions’ to mefloquine, self-described by the respondents, were reported more 
frequently than reactions to doxycycline or primaquine.  This difference was greatest in the East Timor 
study where 20% (13/66) of mefloquine users reported side effects.  Over half of the reactions to 
mefloquine described were related to nightmares and disturbed sleep, which are considered 
‘common’ side effects [9].  In contrast, photosensitivity and nausea were the most commonly reported 
reactions to doxycycline and primaquine respectively, which are also known side effects of each 
medication [8, 10].  From the questions asked in the study we are unable to determine the duration 
of these reported side effects, however, between 56% and 64% of respondents sought medical advice 
for their reaction.  
 
Members who reported that they ‘mostly’ used mefloquine generally had higher scores on the K10 
and PCL-C scales, which measure symptoms of anxiety and depression, and post-traumatic stress 
respectively.  However, these results were not consistently observed.  For example, there was no 
association between using mefloquine and symptoms of PTSD in the East Timor study.   
 
Clinical significance is defined as a change which has a noticeable effect on daily life [23].  While some 
comparisons showed mefloquine users had a statistically significantly higher mental health scale score 
compared to other groups, the differences observed were below the levels regarded as ‘clinically 
significant’ (K10 > 6.73, PCL-C >10) in studies of treatment and improvement in patients [24, 25].  The 
analyses undertaken did not show any association between doxycycline or primaquine use and self-
reported mental health.   
 
Bougainville veterans who used ‘mostly’ mefloquine on deployment were more likely to report their 
health as ‘fair or poor’ compared to those who used doxycycline (OR 3.13 95% CI (1.11, 8.85)).  
Bougainville veterans who used mefloquine also reported a higher number of mean health symptoms 
in the previous month compared to non-mefloquine users.  Neither of these results were replicated 
in the East Timor study.   
 
The reasons for the differences in the results between the East Timor and Bougainville studies is 
unknown.  The numbers who reported changing from using doxycycline to mefloquine were similar in 
the East Timor (29%) and Bougainville groups (37%). Two trials of anti-malarial drugs that used 
mefloquine as a trial or comparator drug occurred during the East Timor deployment (mefloquine 
groups n=162 and n=1157) [4, 5], whereas mefloquine was not used in the tafenoquine trial which 
occurred in Bougainville [2].  Therefore members who received mefloquine in East Timor may have 
been more likely to have received this drug as part of a clinical trial compared to Bougainville veterans. 
 
The analysis of open-ended question responses shows that in these 2007 and 2008 studies a small 
number of respondents (1.6%) raised concerns about anti-malarial drug use.  The larger frequency of 
comments about doxycycline use is understandable given this was the most common anti-malarial 
drug used. Sixteen respondents in total provided a negative comment about the use of mefloquine or 
the anti-malarial drug trials. These results document that there was some concern about the use of 
anti-malarial drugs on deployment and the possible health effects in 2007-2008.    
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4.3 Comparison with similar research 
 
The percentage of East Timor veterans who reported a ‘significant reaction’ to mefloquine (19.7%) 
was lower than the percentages reported to have had a moderate or severe ‘adverse reaction’ to 
mefloquine during one of the East Timor trials (30%) [4].  The current study collected this information 
a number of years after the deployment which may partly explain this difference in percentages.  
 
Unlike the Schneiderman et al study [16], the present study did find some significant associations 
between adverse long-term mental and physical health outcomes and use of mefloquine. As noted, 
our findings are based on small numbers of veterans who reported taking mefloquine, whereas the 
Schneiderman study had an overall sample size of over 19,000 and a total of 346 who reported using 
mefloquine.  Like this US study, the present study found minimal short-term and no long-term adverse 
health outcomes from the use of primaquine. Both studies used validated scales to measure health 
outcomes of concern (both used the PCL-C). 
 
A US study of Peace Corps Volunteers found that psychiatric diagnoses were higher in a mefloquine 
group, but that these results were not replicated when participants with prior psychiatric illness were 
excluded from the analysis [32].  Eick-Cost et al. also undertook a large study of mefloquine exposure 
and neuropsychiatric outcomes. This study assessed outcomes for one year before and after a 
prescription of the drug. Overall this US study did not find an association between mefloquine use and 
neuropsychiatric diagnoses, but it was noted that mefloquine users with a previous neuropsychiatric 
diagnosis may be at increased risk of adverse outcomes [33].   
 
The analyses presented in this report were unable to identify or exclude respondents who had a 
psychiatric illness prior to the deployment due to the cross-sectional design. 
 
4.4 Strengths and limitations  
 
A strength of this study is the time period in which data collection occurred, which was prior to 
extensive publicity regarding antimalarial drug use in the military. Presently, numerous military 
member perceptions of experiences with anti-malarial drugs, particularly mefloquine, can be found 
on social media platforms and in quotes provided to traditional media. A Google News Search 
performed in September 2018 revealed that sustained media interest in the topic of mefloquine use 
in the military is evident over the last decade [34].  
 
The data collection for the Bougainville, Solomon Islands and East Timor Health Studies in 2007-2008 
largely pre-dates the widespread use of social media platforms and media interest in the topic. 
Therefore, attributions of adverse reactions to mefloquine and responses to open-ended questions in 
the studies may be less socially influenced than if they had been obtained today. However, in 2004, a 
law firm announced plans to launch a class action against the ADF on behalf of Australian soldiers who 
took mefloquine and this received media attention [35]. An event like this, which predated the data 
collection for the current study, could have influenced some participant’s self-reported responses 
collected in 2007-2008.  
 
Recall bias may have been a limitation in this study.  This study relied on self-reported questions on 
anti-malarial use and required respondents to recall types of medications taken a number of years 
 30 
 
prior. Additionally it was difficult to examine the association between a specific anti-malarial drug and 
subsequent health, because most respondents reported taking an anti-malarial on deployment (e.g. 
doxycycline or mefloquine) and primaquine on return to Australia.  Comparisons are further 
complicated by the possibility that respondents may have used different anti-malarial drugs on 
different deployments. 
 
This study was a secondary exploratory analysis of data collected in 2007-2008, as opposed to a new 
study specifically designed and powered to assess the association between anti-malarial drug use and 
health outcomes. As such, this study was limited by small numbers of members who reported using 
mefloquine in each deployment location. As such the study had limited power to detect statistically 
significant differences between the mefloquine and doxycycline treatment groups, and the results 
presented are therefore largely descriptive in nature.   
 
The cross-sectional design of the original studies allowed us to investigate associations between 
different types of anti-malarial use on deployment and self-reported physical and mental health 
outcomes.  The data presented provides a snapshot of associations between anti-malarial use and 
health in 2007-2008.  However, we do not know whether health problems may have predated the 
deployment or anti-malarial drug use, because the data collected was not longitudinal in design.   
 
While we adjusted for self-reported traumatic exposures on deployment in our assessment of mental 
health outcomes, there are many other pathways through which a respondents’ health may be 
affected by a military deployment (e.g. deployment stressors, injury on deployment, living conditions, 
exposure to environmental hazards) [36].  While the results presented highlight associations between 
some types of anti-malarial use and self-reported health, we are unable to investigate causal 
relationships from the available data due to small numbers and the cross-sectional design.   
 
4.5 Discussion summary 
Since 2006 mefloquine has been used as the third-line anti-malarial in the ADF, meaning it is only used 
when doxycycline or malarone is not available or appropriate [6].  The results presented in this report 
indicated that mefloquine users in Bougainville reported poorer self-rated health and more general 
health symptoms than the group who used doxycycline.  However, these results were based on a small 
number of mefloquine users in Bougainville (n=27) and the findings were not replicated in the East 
Timor group.   
It is recommended that any future trials of anti-malarial drug use in the ADF allow for an assessment 
of both short term and medium-term health following drug administration, as the Repatriation 
Medical Authority report highlighted that there were comparatively few studies designed to assess 
possible longer-term effects of anti-malarial drug use [1].   
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